

Saad S Kenderian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8506123/publications.pdf>

Version: 2024-02-01

117
papers

4,233
citations

201658

27
h-index

123420

61
g-index

119
all docs

119
docs citations

119
times ranked

5551
citing authors

#	ARTICLE	IF	CITATIONS
1	Human chimeric antigen receptor macrophages for cancer immunotherapy. <i>Nature Biotechnology</i> , 2020, 38, 947-953.	17.5	692
2	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. <i>Journal of Clinical Investigation</i> , 2016, 126, 3814-3826.	8.2	472
3	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. <i>Blood</i> , 2019, 133, 697-709.	1.4	408
4	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CART T Cell Immunotherapy for Acute Myeloid Leukemia. <i>Cell</i> , 2018, 173, 1439-1453.e19.	28.9	323
5	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 2684-2696.	7.0	157
6	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. <i>Cancer Discovery</i> , 2017, 7, 1154-1167.	9.4	149
7	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2395-2407.	1.4	148
8	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 1973.	4.8	148
9	Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. <i>BioDrugs</i> , 2017, 31, 473-481.	4.6	105
10	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
11	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
12	Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. <i>Lancet Haematology</i> , the, 2020, 7, e816-e826.	4.6	84
13	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2382-2394.	3.0	77
14	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 235-246.	2.0	76
15	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773.	3.5	64
16	CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 69-77.	4.4	60
17	Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. <i>Blood</i> , 2016, 127, 1960-1966.	1.4	56
18	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 3708-3721.	1.4	53

#	ARTICLE	IF	CITATIONS
19	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. <i>Immunotherapy</i> , 2019, 11, 851-857.	2.0	48
20	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47
21	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021, 29, 1529-1540.	8.2	43
22	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719.	1.3	42
23	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018, 183, 421-427.	2.5	37
24	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020, 9, 3390-3399.	2.8	36
25	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 1376-1383.	1.3	33
26	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021, 100, 143-155.	1.8	32
27	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. <i>Blood</i> , 2016, 128, 652-652.	1.4	31
28	Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. <i>Modern Pathology</i> , 2015, 28, 367-372.	5.5	30
29	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S19-S21.	2.0	26
30	Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	24
31	The Microbiome and Immune Regulation After Transplantation. <i>Transplantation</i> , 2017, 101, 56-62.	1.0	22
32	<i>t(12;21)(p13;q22)</i> translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019, 94, 338-345.	4.1	19
33	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	4.1	19
34	CART Cell Toxicities: New Insight into Mechanisms and Management. <i>Clinical Hematology International</i> , 2020, 2, 149.	1.7	19
35	Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 253-264.	2.3	17
36	Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S19-S20.	2.0	17

#	ARTICLE	IF	CITATIONS
37	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
38	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020, 105, 2675-2678.	3.5	17
39	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 2052-2063.	1.3	16
40	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018, 103, e237-e240.	3.5	15
41	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	3.7	15
42	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	1.3	15
43	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. <i>Current Opinion in Hematology</i> , 2020, 27, 41-48.	2.5	14
44	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. <i>Neurologic Clinics</i> , 2020, 38, 953-963.	1.8	14
45	InÂvivo CART cell imaging: Paving the way for success in CART cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 625-633.	4.4	14
46	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021, 11, 86.	6.2	14
47	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	3.4	14
48	Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity. <i>Blood</i> , 2015, 126, 565-565.	1.4	14
49	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017, 92, 1362-1369.	4.1	13
50	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. <i>Blood</i> , 2015, 126, 852-852.	1.4	13
51	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98.	4.1	13
52	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 865-865.	1.4	12
53	GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. <i>Leukemia</i> , 2022, 36, 1635-1645.	7.2	12
54	Racial and Sex Differences in Presentation and Outcomes of Small Cell Lung Cancer in the United States: 1973 to 2010. <i>Chest</i> , 2015, 147, e164-e165.	0.8	11

#	ARTICLE	IF	CITATIONS
55	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 203-210.	2.4	10
56	CRISPR Takes the Front Seat in CART-Cell Development. BioDrugs, 2021, 35, 113-124.	4.6	10
57	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. American Journal of Hematology, 2020, 95, E57-E60.	4.1	9
58	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. Blood, 2016, 128, 766-766.	1.4	9
59	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. Blood Cancer Journal, 2022, 12, 18.	6.2	9
60	Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Experimental Hematology, 2022, 108, 1-7.	0.4	9
61	Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. British Journal of Haematology, 2022, 199, 239-244.	2.5	9
62	Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. Methods in Molecular Biology, 2017, 1633, 267-276.	0.9	8
63	ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleuce (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). Blood, 2020, 136, 6-7.	1.4	8
64	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer Journal, 2021, 11, 47.	6.2	7
65	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2015, 126, 2523-2523.	1.4	7
66	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 50-51.	1.4	7
67	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer Journal, 2021, 11, 140.	6.2	6
68	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleuce Therapy for Lymphoma. Blood, 2019, 134, 4106-4106.	1.4	6
69	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. Blood, 2019, 134, 3868-3868.	1.4	6
70	Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy. Blood, 2020, 136, 6-7.	1.4	6
71	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.	6.2	6
72	CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, S25-S26.	2.0	5

#	ARTICLE	IF	CITATIONS
73	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. <i>Clinical Cancer Research</i> , 2020, 26, 5759-5771.	7.0	5
74	273. Genome Editing Using CRISPR-Cas9 to Increase the Therapeutic Index of Antigen-Specific Immunotherapy in Acute Myeloid Leukemia. <i>Molecular Therapy</i> , 2016, 24, S108.	8.2	4
75	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. <i>British Journal of Haematology</i> , 2018, 182, 141-145.	2.5	4
76	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 738-746.	1.2	4
77	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568.	1.4	4
78	Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogenic Stem Cell Transplant Recipient. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 387-391.	2.4	3
79	Chimeric Antigen Receptor Tâ€Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside. <i>Clinical and Translational Science</i> , 2018, 11, 537-539.	3.1	3
80	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019, 134, 4306-4306.	1.4	3
81	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019, 134, 3050-3050.	1.4	3
82	Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1000-1000.	1.4	3
83	Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. , 2015, 3, .		2
84	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. <i>Blood</i> , 2019, 134, 53-53.	1.4	2
85	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018, 132, 586-586.	1.4	2
86	Differential transcriptomic profiling in ibrutinibâ€naÃ-ve versus ibrutinibâ€resistant Richter syndrome. <i>Hematological Oncology</i> , 2022, 40, 302-306.	1.7	2
87	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€graft versus hostâ€™-like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 1879-1881.	2.4	1
88	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S224.	2.0	1
89	Upregulation of AXL and Î²-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. <i>Blood Cancer Journal</i> , 2021, 11, 37.	6.2	1
90	In Reply â€ Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. <i>Mayo Clinic Proceedings</i> , 2021, 96, 817-818.	3.0	1

#	ARTICLE	IF	CITATIONS
91	The prognostic significance of $\langle scp \rangle del6q23 \langle /scp \rangle$ in chronic lymphocytic leukemia. American Journal of Hematology, 2021, 96, E203-E206.	4.1	1
92	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 679-679.	1.4	1
93	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. Blood, 2020, 136, 39-40.	1.4	1
94	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. Blood, 2021, 138, 901-901.	1.4	1
95	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. Blood, 2020, 136, 30-31.	1.4	1
96	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. Blood, 2020, 136, 3-4.	1.4	1
97	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. Blood, 2020, 136, 30-31.	1.4	1
98	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 16-17.	1.4	1
99	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 49-50.	1.4	1
100	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. Experimental Hematology, 2022, 111, 32-40.	0.4	1
101	Abstract 3139: CD33 directed chimeric antigen receptor T cell therapy as a novel regimen prior to allogeneic stem cell transplantation in acute myeloid leukemia. , 2015, , .		0
102	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. Blood, 2016, 128, 5585-5585.	1.4	0
103	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. Blood, 2016, 128, 300-300.	1.4	0
104	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. Blood, 2016, 128, 3228-3228.	1.4	0
105	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. Blood, 2018, 132, 1857-1857.	1.4	0
106	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. Blood, 2019, 134, 5352-5352.	1.4	0
107	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 4500-4500.	1.4	0
108	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. Blood, 2019, 134, 3037-3037.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. Blood, 2019, 134, 3300-3300.	1.4	0
110	A Phase 2/3 Randomized, Placebo-Controlled, Open-Label, Multi-Center Trial of Lenzilumab to Improve the Safety and Efficacy of CAR-T Cell Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma (The SHIELD Study). Blood, 2021, 138, 1758-1758.	1.4	0
111	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-na ⁺) or after Progression on Sequential I and V (Double-Refractory). Blood, 2021, 138, 1560-1560.	1.4	0
112	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. Blood, 2020, 136, 26-27.	1.4	0
113	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. Blood, 2020, 136, 10-12.	1.4	0
114	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. Blood, 2020, 136, 28-29.	1.4	0
115	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13.	1.4	0
116	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 1-1.	1.4	0
117	Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸ F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography. Journal of Visualized Experiments, 2022, , .	0.3	0